Beneficial Ownership Report · SCHEDULE 13G/A
Jaguar Health, Inc.
JAGXNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Jaguar Health, Inc.
- Company CIK
- 0001585608
- Street
- 200 Pine Street, Suite 400
- City
- San Francisco
- State / country code
- CA
- Postal code
- 94104
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.0001 per share
- Event date
- 09/12/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Joshua Mailman
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 189,617.00
- Percent of class
- 9.99
- Sole voting power
- 186,205.00
- Shared voting power
- 3,412.00
- Sole dispositive power
- 186,205.00
- Shared dispositive power
- 3,412.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Jaguar Health, Inc.
Principal executive office address
200 Pine Street, Suite 400 San Francisco, California
Item 2
Citizenship
Joshua Mailman is a United States citizen.
Filing person
This Schedule 13G is being filed by Joshua Mailman ("Mr. Mailman").
Principal business or residence address
The principal business office of the Reporting Person is: c/o Citrin Cooperman 50 Rockefeller Plaza, 4th Floor New York, NY 10020
Item 3
Not applicable indication
Y
Item 4
Percent of class
9.99%
Amount beneficially owned
189,617
Sole voting power
186,205
Shared voting power
3,412
Sole dispositive power
186,205
Shared dispositive power
3,412
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- Joshua Mailman
- Signed
- /s/ Joshua Mailman
- Title
- Joshua Mailman
- Date
- 09/24/2026
Company context
Jaguar was founded in San Francisco, California, as a Delaware corporation on June 6, 2013 (“inception”). The Company was a majority-owned subsidiary of Napo until the close of the Company’s initial public offering on May 18, 2015. The Company was formed to develop and commercialize first-in-class prescription and non-prescription products for companion animals. On July 31, 2017, Jaguar completed a merger with Napo pursuant to the Agreement and Plan of Merger dated March 31, 2017, by and among Jaguar, Napo, Napo Acquisition Corporation (“Merger Sub”), and Napo’s representative (the “Merger Agreement”). In accordance with the terms of the Merger Agreement, upon the completion of the merger, Merger Sub merged with and into Napo, with Napo surviving as the wholly owned subsidiary (the “Merger” or “Napo Merger”). Immediately following the Merger, Jaguar changed its name from “Jaguar Animal Health, Inc.” to “Jaguar Health, Inc.” Napo now operates as a wholly owned subsidiary of Jaguar focused on human health, including the ongoing development of crofelemer and commercialization of Mytesi.
Current securities
Recent company filings
- PRER14A filingSep 29, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other EventsSep 28, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other EventsSep 25, 2026
- 424B5 filingSep 24, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other EventsSep 24, 2026